选择语言

Human VSIG3 Protein, Fc Tag

用户评价
货号-规格
价格
Qty.
VS3-H5258-100ug
¥3675.00
VS3-H5258-1mg (500ug X 2)
¥24255.00
合计0件 产品金额¥ 0

产品详情

  • 分子别名(Synonym)

    VSIG3,IgSF11,CXADRL1,Bt-IgSF,CT119

  • 表达区间及表达系统(Source)

    Human VSIG3, Fc Tag (VS3-H5258) is expressed from human 293 cells (HEK293). It contains AA Leu 23 - Gly 241 (Accession # Q5DX21-1).

    Predicted N-terminus: Leu 23

    Request for sequence
  • 蛋白结构(Molecular Characterization)

    VSIG3 Structure

    This protein carries a human IgG1 Fc tag at the C-terminus.

    The protein has a calculated MW of 49.7 kDa. The protein migrates as 60-65 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • 偶联(Conjugate)

    Unconjugated

  • 内毒素(Endotoxin)

    Less than 1.0 EU per μg by the LAL method.

  • 纯度(Purity)

    >95% as determined by SDS-PAGE.

  • 制剂(Formulation)

    Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • 重构方法(Reconstitution)

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • 存储(Storage)

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • 质量管理控制体系(QMS)

    1. 质量管理体系(ISO, GMP)
    2. 质量优势
    3. 质控流程

数据展示

  • 电泳(SDS-PAGE)

    VSIG3 SDS-PAGE

    Human VSIG3, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

  • 活性(Bioactivity)-ELISA

     VSIG3 ELISA

    Immobilized Human VSIG3, Fc Tag (Cat. No. VS3-H5258) at 5 μg/mL (100 μL/well) can bind Human B7-H5, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. B75-H5258) with a linear range of 0.313-10 μg/mL (Routinely tested).

    Protocol
  • 活性(Bioactivity)-SPR

     VSIG3 SPR

    Human B7-H5, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. B75-H5258) Captured on CM5 chip via anti-mouse antibodies surface can bind Human VSIG3, Fc Tag (Cat. No. VS3-H5258) with an affinity constant of 8.87 μM as determined in a SPR assay (Biacore T200) (Routinely tested).

    Protocol
  •  VSIG3 SPR

    Human VSIG3, Fc Tag (Cat. No. VS3-H5258) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human B7-H5, His Tag (Cat. No. B75-H52H0) with an affinity constant of 53.4 μM as determined in a SPR assay (Biacore T200) (Routinely tested).

    Protocol
  • 活性(Bioactivity)-BLI

     VSIG3 BLI

    Loaded Human VSIG3, Fc Tag (Cat. No. VS3-H5258) on AHC Biosensor, can bind Human B7-H5, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. B75-H5258) with an affinity constant of 3.7 μM as determined in BLI assay (ForteBio Octet Red96e) (QC tested).

    Protocol
  •  VSIG3 BLI

    Loaded Biotinylated Human B7-H5, Avitag,His Tag (Cat. No. B75-H82E1) on SA Biosensor, can bind Human VSIG3, Fc Tag (Cat. No. VS3-H5258) with an affinity constant of 0.312 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

    Protocol
  •  VSIG3 BLI

    Loaded Biotinylated Human B7-H5, Fc,Avitag (Cat. No. B75-H82F3) on SA Biosensor, can bind Human VSIG3, Fc Tag (Cat. No. VS3-H5258) with an affinity constant of 0.617 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

    Protocol

用户评价
发表评论

背景介绍

VSIG3, also known as IGSF11, BT-IgSF, and CLMP, is a homophilic adhesion molecule that preferentially expressed in the brain. The function of VSIG3 is to stimulate cell growth through homophilic interactions. In clinical, the VSIG3 has been reported to as a novel target for cancer immunotherapy of gastrointestinal and hepatocellular carcinomas. In addition, VSIG-3 is also a ligand of B7 family member VISTA/PD-1H and inhibits human T-cell functions through a novel VSIG-3/VISTA pathway. VSIG-3/VISTA co-inhibitory pathway may provide new strategies for the treatment of human cancers and autoimmune disorders.

前沿进展

 
联系我们
项目合作
查看更多项目
  • 产品基础信息
  • 产品详情
  • 数据展示
  • 用户评价
  • 背景介绍